Jung-Mo Ahn, Ph.D.
Affiliations: | 2000 | University of Arizona, Tucson, AZ | |
| 2004- | University of Texas at Dallas, Richardson, TX, United States |
Area:
Organic Chemistry, Biochemistry, Chemical Biology and Medicinal ChemistryWebsite:
https://www.utdallas.edu/chemistry/faculty/ahn.htmlGoogle:
"Jung-Mo Ahn"Bio:
https://www.utdallas.edu/~jungmo.ahn/drahn.html
https://arizona.openrepository.com/handle/10150/284301
DOI: 10.1021/jm500810s
(Show more)
Parents
Sign in to add mentor| Victor J. Hruby | grad student | 2000 | University of Arizona | |
| (Search for bioactive conformation of glucagon and development of potent glucagon antagonists.) | ||||
| Kim David Janda | post-doc | 2001-2004 | Scripps Institute | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Viswanadhapalli S, Ma S, Lee TK, et al. (2020) Abstract 5676: Preclinical evaluation of estrogen receptor coregulator binding inhibitor ERX-245 in breast cancer Cancer Research. 80: 5676-5676 |
| Raj GV, Liu X, Ekoue D, et al. (2019) Abstract 26: Development of potent lead compounds in multiple tumor types Cancer Research. 79: 26-26 |
| Raj GV, Sareddy GR, Ma S, et al. (2017) Author response: Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers Elife |
| Graaf C, Donnelly D, Wootten D, et al. (2016) Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. Pharmacological Reviews. 68: 954-1013 |
| Vadlamudi RK, Sareddy GR, Viswanadhapalli S, et al. (2016) Abstract B08: ESR1 coregulator binding site inhibitors (ECBIs) as novel therapeutics to target hormone therapy-resistant breast cancer Molecular Cancer Research. 14 |
| Vadlamudi RK, Sareddy GR, Viswanadhapalli S, et al. (2016) Abstract 860: ESR1 coregulator binding inhibitor (ECBI): a novel agent for treating hormone therapy-resistant breast cancer Cancer Research. 76: 860-860 |
| Gao H, Niu G, Yang M, et al. (2011) PET of insulinoma using ¹⁸F-FBEM-EM3106B, a new GLP-1 analogue. Molecular Pharmaceutics. 8: 1775-82 |
| Murage EN, Gao G, Bisello A, et al. (2010) Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. Journal of Medicinal Chemistry. 53: 6412-20 |
| Murage E, Beinborn M, Ahn JM. (2009) Seeking for alpha-helical propensity in a receptor-bound conformation of glucagon-like peptide-1. Advances in Experimental Medicine and Biology. 611: 289-90 |
| Ahn JM, Han SY, Murage E, et al. (2009) Rational design of peptidomimetics for class B GPCRs: potent non-peptide GLP-1 receptor agonists. Advances in Experimental Medicine and Biology. 611: 125-6 |